Comparable Study of Different Radiation Dose in Esophageal Carcinoma

Status Recruiting

Clinical Trial Summary

Radiation therapy plus concurrent chemotherapy is now the standard therapy for patients with localized carcinoma of the esophagus selected for nonsurgical treatment. The standard radiation dose is 50-50.4Gy/1.8-2.0Gy/F.All of this were based on 2D radiation technology. Entering new century, 3D-CRT or IMRT has used on esophageal cancer. In China,the recommend radiation dose of concurrent chemoradiation was 60Gy. The study is a clinical phase III, randomized trial to compare the different radiation dose(60Gy vs 50Gy) of concurrent chemoradiation using 3D-CRT or IMRT in patients with unresectable esophageal carcinoma.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01937208
Study type	Interventional
Source	Zhejiang Cancer Hospital
Contact	xiao zheng, MD
Phone	0086-571-88122078
Email	zhengxiao@medmail.com
Status	Recruiting
Phase	Phase 3
Start date	August 2013
Completion date	July 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05059444` - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Not yet recruiting	`NCT05996484` - Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma	Phase 2
Recruiting	`NCT02355249` - Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer	Phase 3
Completed	`NCT01691625` - Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer	N/A
Not yet recruiting	`NCT05937438` - Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma	Phase 1/Phase 2
Recruiting	`NCT05777707` - Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma	Phase 1/Phase 2
Recruiting	`NCT02527057` - Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer	N/A
Withdrawn	`NCT00636298` - Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy	Phase 2
Recruiting	`NCT06009705` - Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer
Recruiting	`NCT04652180` - Robot-assisted Thoracic Approach Versus Open Transthoracic Esophagectomy .	N/A
Recruiting	`NCT04147494` - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues	Early Phase 1
Withdrawn	`NCT03220009` - Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma	Phase 2
Recruiting	`NCT06199895` - Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer	Phase 2
Completed	`NCT00590031` - Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.	Phase 2
Active, not recruiting	`NCT00176800` - Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma	Phase 2
Completed	`NCT03099382` - Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer	Phase 3
Active, not recruiting	`NCT04607590` - Yoga Program for Improving the Quality of Life in Couples Coping With Cancer
Recruiting	`NCT00991094` - Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Completed	`NCT01855854` - Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH	Phase 2
Recruiting	`NCT06265285` - Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	Phase 2